Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus.
Schorlemmer
H U
HU
Research Laboratories Hoechst Marion Roussel Deutschland GmbH, Wiesbaden, Germany.
Bartlett
R R
RR
Lindner
J K
JK
Kurrle
R
R
D020106:Acrylamide / Q000627:therapeutic use; D000178:Acrylamides; D000480:Alkynes; D000818:Animals; D002208:Caproates / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles; D009570:Nitriles; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D016038:Skin Transplantation / Q000276:immunology*; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D000178:Acrylamides; D000480:Alkynes; D002208:Caproates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; D020106:Acrylamide; C116406:HMR 1279; D016559:Tacrolimus